Indian pharma companies are well positioned to generate strong revenues from the US generics market thanks to the receipt of many abbreviated new drug application (ANDA) approvals from the US FDA. Out of the 255 ANDA approvals by the US FDA from January to July 2013, Indian generic players received 103 approvals (which accounts for over 40%). This has placed Indian generics manufacturers as leading global players. Among Indian generic firms, Aurobindo Pharma, Dr Reddy's Labs and Sun Pharma have emerged as strong contenders in the US generic market due to their integration and vast product portfolio.
展开▼
